News – Page 734 – Endpoints News

Bristol Myers scales up cell therapy production with liso-cel nod in hand and another approval maybe on the way

5 years ago

Biotech upstart adds a failed Merck KGaA drug to the pipeline, mapping new combo approach to MAPK pathway

5 years ago

Stephen Hahn makes first post-FDA move, joining board of under-the-radar Philadelphia company

5 years ago

Fueled by Covid prospects, Chinese vaccine developer scores $230M to upscale the whole pipeline

5 years ago

Beam turns its soaring valuation into new assets, buying out an under-the-radar spinout and their gene delivery tech

5 years ago

Catalent uncorks play in plasmid DNA with buyout of Belgian neighbor Delphi, Maryland expansion launch

5 years ago

NeuroRx chief lines up Hail Mary for once-rejected Covid-19 drug

5 years ago

Biopharma's success rate in bringing drugs to market has long been abysmal. Can new tools help rewrite that troubled ...

5 years ago

Intercept shakeup continues as CMO, former NASH chief resigns. Is the NASH biotech abandoning its flagship disease?

5 years ago

Covid-19 roundup: Pfizer, Moderna say Biden's goal of having 600M doses by July is within sight; EMA to consider ...

5 years ago

FDA issues new recommendations to take on Covid-19 variants

5 years ago

Libtayo scores second OK in two weeks, this time for front-line NSCLC. Can it take on Keytruda?

5 years ago

Jim Mullen won a $20M option package when he switched from chairman to the CEO job at Editas — and it's all tied to ...

5 years ago

Kite development head Ken Takeshita jumps to Daiichi Sankyo amid oncology push

5 years ago

Amgen lines up expansion to Otezla's $13B franchise; China OKs 'breakthrough' use of PD-1

5 years ago

After a slow week, the IPO train is back up and running as 3 more biotechs hop aboard

5 years ago

Despite red flag from FDA, controversial ALS cell therapy developer says it may still march ahead anyway

5 years ago

Is biotech the new bitcoin? A top analyst draws some uncomfortable comparisons to a certain cryptocurrency as ...

5 years ago

Eli Lilly's David Ricks snared $24M pay package in a year turbo-boosted by Covid-19 antibody

5 years ago

A diagnostics company completes its pharma makeover, rebranding as Fore with Immunomedics vet at the helm

5 years ago

Otonomy's resurrected ear drug is now dead again — and investors aren't hanging around

5 years ago

Covid-19 roundup: Serum Institute chief asks countries to 'please be patient'; Sanofi and GlaxoSmithKline enter PhII ...

5 years ago

Vas Narasimhan gets a bump in pay, but still falls well below some rivals

5 years ago

A year after trial failure, AstraZeneca withdraws Imfinzi's maiden indication in bladder cancer — but execs look to ...

5 years ago

First page Previous page 731 732 733734735 736 737 Next page Last page